Safety, Immunogenicity, and Hemostatic Efficacy of Nonacog Gamma in Patients With Severe or Moderately Severe Hemophilia B: A Continuation Study

This phase 3, prospective, open-label, multicenter, continuation study (NCT01286779) investigated the use of a recombinant factor IX (FIX), nonacog gamma (BAX 326, RIXUBIS(®)) in patients with severe or moderately severe hemophilia B. The study population included 85 patients transitioning from a ph...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Appl Thromb Hemost
Hauptverfasser: Windyga, Jerzy, Stasyshyn, Oleksandra, Lissitchkov, Toshko, Mamonov, Vasily, Serban, Margit, Rusen, Luminita, Ploder, Bettina, Tangada, Srilatha
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2020
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7469725/
https://ncbi.nlm.nih.gov/pubmed/32866032
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620950836
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge